Al-Taie, Anmar2022-06-152022-06-152022Al-Taie A. Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies beyond COVID-19 Vaccination. Disaster Med Public Health Prep. 2022 Jun 8:1-5. doi: 10.1017/dmp.2022.150. Epub ahead of print. PMID: 35672931.1935-7893http://doi.org/10.1017/dmp.2022.150https://hdl.handle.net/20.500.12713/2903Nearly three years after its detection, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome CoV-2, is still a life-threatening global pandemic health disease that contributed to a high progression and mortality. This imposes the scientific researching efforts to hold intense interest directed to explore for the development and optimizing different interventions to COVID-19 infection. This commentary summarizes the potential clinical benefits for the recently authorized immunotherapy combination of tixagevimab and cilgavimab monoclonoal antibodies for the prevention and treatment of COVID-19.eninfo:eu-repo/semantics/closedAccessCilgavimabCOVID-19Monoclonal AntibodiesTixagevimabVaccinationArticle35672931WOS:0008288915000012-s2.0-85131923111Q310.1017/dmp.2022.150Q2